pipette
ESEspañol

B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition

Sangwoo S. Kim, Sayuri Miyauchi, Riley N. Jones, Elizabeth Weihe, Lin Zhang, Jamillah Murtadha, Stephen T. Ryan, Shumei Kato, Razelle Kurzrock, Jason Keith Sicklick, Ezra E.W. Cohen, Sandip Pravin Patel, Sarah G Boles, Kathryn Ann Gold, Gregory P. Botta, Hitendra Patel, Rebecca Arielle Shatsky, Susan M. Kaech, Roy S, P. Dominick Sanders, James Don Murphy, Christopher J. Kane, Emily I. Pittman, Jingjing Zou, Minya Pu, Natalie E. Quach, Jorge Silvio Gutkind, Karen S. Messer, Diane Simeone, Loren K. Mell, Joseph A. Califano, Christina A. M. Jamieson, Arno James Mundt, Andrew B. Sharabi

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Here, we report results from a prospective randomized phase 2 trial of 106 patients treated with immune checkpoint inhibitors (ICIs) and identify that B cell antibody responses are associated with exceptional complete responses to ICI in certain cancer types.

Appeared: Friday, October 30. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.adv7928